uniQure Announces License Agreement with CSL Behring to Commercialize Hemophilia B Gene Therapy
June 24, 2020 16:05 ET
|
uniQure Inc.
~ CSL Behring Obtains Exclusive Global Rights to Develop and Commercialize uniQure’s Differentiated Gene Therapy Candidate for Hemophilia B ~ ~ uniQure Eligible to Receive More Than $2 Billion,...
uniQure Announces First Two Patients Treated in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
June 19, 2020 07:05 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, June 19, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
uniQure Announces the Appointment of Leonard E. Post, Ph.D. to its Board of Directors
June 17, 2020 16:05 ET
|
uniQure Inc.
~ Biopharma Executive Brings 35 Years of Research and Development Leadership ~ LEXINGTON, Mass. and AMSTERDAM, June 17, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy...
uniQure Announces First Quarter 2020 Financial Results and Highlights Recent Company Progress
April 29, 2020 07:00 ET
|
uniQure Inc.
~ Completed Target Patient Dosing in Phase III HOPE-B Trial of Etranacogene Dezaparvovec in Hemophilia B ~ ~ Announced 22 Presentations at Upcoming ASGCT Virtual Annual Meeting ~ LEXINGTON, Mass....
uniQure to Participate in Multiple Upcoming Investor Conferences in April
March 30, 2020 07:00 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, March 30, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
uniQure to Participate in Multiple Upcoming Industry Conferences in March
March 03, 2020 07:00 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, March 03, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
uniQure and Gen-X Enter into Research Collaboration and License Agreement for the Development of Novel Synthetic Promoters
March 02, 2020 16:05 ET
|
uniQure Inc.
~ Gen-X Will Work with uniQure During an Exclusivity Period to Identify Novel Promoters for uniQure’s Product Portfolio ~ ~ uniQure Receives Option to Acquire Gen-X Business for Use in Gene Therapy ~...
uniQure Announces 2019 Financial Results and Highlights Recent Company Progress
March 02, 2020 16:05 ET
|
uniQure Inc.
~ Patient Dosing Nearly Completed in Phase III HOPE-B Trial of Etranacogene Dezaparvovecin Hemophilia B ~ ~ First Patient Procedure in Phase I/II Clinical Trial of AMT-130 in Huntington’s Disease...
uniQure to Participate in Multiple Upcoming Industry Conferences in December
December 02, 2019 07:00 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Dec. 02, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
uniQure to Participate in Multiple Upcoming Industry Conferences in November
November 01, 2019 07:00 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Nov. 01, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...